Department of Pharmacology and Toxicology, School of Pharmaceutical Sciences, Sun Yat-Sen University (Higher Education Mega Center), 132# East Wai-huan Road, Guangzhou, 510006, Guangdong, People's Republic of China.
Naunyn Schmiedebergs Arch Pharmacol. 2018 Dec;391(12):1373-1385. doi: 10.1007/s00210-018-1556-7. Epub 2018 Aug 21.
Protocatechuic aldehyde (PCA) is a natural compound found in the Chinese herb Salvia miltiorrhiza. It has been shown to possess multiple biological activities and to protect the cardiovascular system against oxidative stress, inflammation, and atherosclerosis. However, the potential effects of PCA on cardiac hypertrophy remain to be investigated. In this study, we showed that isoproterenol treatment (ISO, 10 μM for 24 h) induced significant hypertrophy in cultured neonatal rat cardiomyocytes, as manifested by enlargement of cell surface area (1.74-fold greater than that of the control, p < 0.05) and upregulation of hypertrophic gene markers (2.44- to 2.75-fold increase in ANF and β-MHC protein expression, p < 0.05). These ISO-induced hypertrophic responses were attenuated by PCA (50-200 μM, p < 0.05). Furthermore, intragastric administration of PCA (10-100 mg/kg/day) ameliorated cardiac hypertrophy in ISO-treated rats (1.5 mg/kg/day, s.c., for 7 days). PCA inhibited the abnormal changes in echocardiographic parameters and suppressed ISO-induced increase in cardiomyocyte cross-sectional area and collagen content (p < 0.05). It also ameliorated ISO-mediated elevation of HW/BW, LVW/BW, and HW/TL ratios (p < 0.05). Mechanistically, ISO facilitated JAK2 and STAT3 phosphorylation, increased STAT3 nuclear translocation, and enhanced STAT3 transcriptional activity. All these changes were attenuated by PCA. Taken together, these findings showed that PCA could protect against cardiac hypertrophy induced by ISO possibly via inhibition of the JAK2/STAT3 signaling pathway, suggesting the potential of PCA as a therapeutic candidate for hypertrophy-associated heart diseases.
原儿茶醛(PCA)是一种天然化合物,存在于中国草药丹参中。已证明它具有多种生物活性,可保护心血管系统免受氧化应激、炎症和动脉粥样硬化的影响。然而,PCA 对心肌肥厚的潜在影响仍有待研究。在这项研究中,我们表明,异丙肾上腺素(ISO)处理(10 μM,24 h)诱导培养的新生大鼠心肌细胞发生显著的肥大,表现为细胞表面积增大(比对照组大 1.74 倍,p < 0.05)和肥大基因标志物上调(ANF 和β-MHC 蛋白表达增加 2.44-2.75 倍,p < 0.05)。这些 ISO 诱导的肥大反应被 PCA(50-200 μM,p < 0.05)减弱。此外,PCA(10-100 mg/kg/天)的胃内给药改善了 ISO 处理大鼠的心肌肥厚(1.5 mg/kg/天,皮下,7 天)。PCA 抑制了超声心动图参数的异常变化,并抑制了 ISO 诱导的心肌细胞横截面积和胶原含量增加(p < 0.05)。它还改善了 ISO 介导的 HW/BW、LVW/BW 和 HW/TL 比值升高(p < 0.05)。在机制上,ISO 促进了 JAK2 和 STAT3 的磷酸化,增加了 STAT3 的核转位,并增强了 STAT3 的转录活性。所有这些变化都被 PCA 减弱。综上所述,这些发现表明,PCA 可以通过抑制 JAK2/STAT3 信号通路来防止 ISO 诱导的心肌肥厚,这表明 PCA 作为与肥厚相关的心脏病的治疗候选物具有潜力。